(compared with the corresponding period a year ago)
- Net sales increased 16.1% to
SEK 130,372m (112,339). Sales growth, including organic sales growth and acquisitions, amounted to 9.8%, of which volume accounted for -3.2%, price/mix for 11.9% and acquisitions for 1.1%. -
Operating profit before amortization of acquisition-related intangible assets (EBITA) increased 74% to
SEK 12,323m (7,097) -
Adjusted EBITA increased 60% to
SEK 14,372m (8,974) and the adjusted EBITA margin increased 3.0 percentage points to 11.0% (8.0) -
Profit for the period increased 81% to
SEK 6,905m (3,818) -
Earnings per share increased to
SEK 9.58 (4.78) and adjusted earnings per share increased 55% toSEK 13.20 (8.50) -
Operating cash flow increased 75% to
SEK 11,755m (6,704) - Return on capital employed increased to 11.3% (7.7) and the adjusted return on capital employed increased 3.7 percentage points to 12.9% (9.2)
CEO'S COMMENTS
Strong quarter with high profitable growth
Higher selling prices, a positive product mix, cost savings and lower costs for raw materials, energy and distribution had a positive impact on earnings. All three business areas developed well with higher sales and higher adjusted EBITA margin. Operating cash flow increased 182% to
Our strategic review of ownership in Vinda and Consumer Tissue Private Label Europe, with the aim of reducing Consumer Tissue's share of the company's total sales, is proceeding according to plan.
Higher sales and innovation
Sales growth, including organic sales growth and acquisitions, amounted to 4.6%. Selling prices were higher and the product mix was better. Volumes were lower, mainly due to the company's focus on profitable growth and thereby decisions to implement restructuring measures in Professional Hygiene and to exit contracts with insufficient profitability in Incontinence Products Health Care and
Sustainability at the core
We are striving to achieve our targets in ESG and for net zero emissions by 2050. In
Summary
We can look back on another quarter with high sales growth and higher EBITA margin, where all business areas made positive contributions through profitable growth and margin improvements. In line with our strategy, we continued to grow in the categories and sales channels with the fastest market growth and highest returns. At the same time, the decisions regarding restructuring in Professional Hygiene and exiting contracts with insufficient profitability in Incontinence Products Health Care and
President and CEO
FUTURE REPORTS
The year-end report for 2023 will be published on
ANNUAL GENERAL MEETING
INVITATION TO PRESENTATION OF THE THIRD QUARTER REPORT FOR 2023
In conjunction with publication, a telephone and web presentation will be held at
Presentation:
Date:
Time:
Link to web presentation: https://essity.videosync.fi/2023-10-26-q3
Telephone:
President and CEO
For further information, please contact:
Sandra Åberg, Vice President Investor Relations, Group Function Finance, +46 (0) 70 564 96 89
Per Lorentz, Vice President Corporate Communications, Group
NB:
This interim report has not been reviewed by the company's auditors.
This information is such that
https://news.cision.com/essity/r/interim-report-quarter-3-2023,c3862328
https://mb.cision.com/Main/15798/3862328/2386286.pdf
(c) 2023 Cision. All rights reserved., source